Altre lingue Synaptogenix, Inc.

Azioni

SNPX

US87167T3005

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 26/04/2024			Variaz. 5gg	Var. 1 gen.
4,53 ^USD	+2,65%		+4,62%	-33,36%

09/04	Synaptogenix, Inc. (NasdaqCM:SNPX) ha acquisito una partecipazione sconosciuta in Psyga Bio Ltd da Cannasoul Analytics Ltd.	CI
03/04	Synaptogenix pianifica un frazionamento azionario inverso 1 a 25; le azioni scendono	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	24/04
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	09/04
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09/04
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	03/04
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	03/04
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	19/12
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	06/12
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology	03/11
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	02/11
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02/11
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28/09/23
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	26/09/23
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K	22/09/23
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	07/09/23
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	20/07/23
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Synaptogenix, Inc.

Azioni

SNPX

US87167T3005

Altre lingue

Filtri